Goldman Sachs Maintains Sell on Seres Therapeutics, Lowers Price Target to $1.25
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani has maintained a 'Sell' rating on Seres Therapeutics (NASDAQ:MCRB) and lowered the price target from $4 to $1.25.
November 03, 2023 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has maintained a 'Sell' rating on Seres Therapeutics and lowered the price target from $4 to $1.25, which could negatively impact the stock's price.
The 'Sell' rating maintained by Goldman Sachs indicates a negative outlook for Seres Therapeutics. The lowering of the price target from $4 to $1.25 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100